Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).
NCT05206591 · Novartis Pharmaceuticals · PHASE3 · withdrawn · last registry update 2023-01-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trial terminated due to strategic decision of senior management” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL17A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-01Results posted on the registry: UCB Biopharma SRL, Bimekizumab (NCT03347110)
- 2023-11-30Results posted on the registry: UCB Biopharma SRL, Bimekizumab (NCT04109976)
- 2023-11-01Phase 3 first posted: Livzon Pharmaceutical Group Inc., LZM012 + Secukinumab (NCT06110676)
- 2023-08-25Phase 3 first posted: UCB Biopharma SRL, Bimekizumab (NCT06011733)
- 2023-08-22Results posted on the registry: Novartis Pharmaceuticals, secukinumab 300 mg Q4W + secukinumab 300 mg Q2W (NCT04300296)
- 2023-08-08Results posted on the registry: UCB Biopharma SRL, Bimekizumab (NCT03766685)
- 2023-08-02Results posted on the registry: Novartis Pharmaceuticals, Secukinumab + Placebo (NCT03713632)
- 2023-07-27Results posted on the registry: UCB Biopharma SRL, Bimekizumab + Certolizumab pegol (NCT03215277)
- 2023-07-12Also stopped (terminated): Inmagene LLC, ABY-035 + Placebo (NCT04795141)
- 2023-06-15Phase 3 first posted: ACELYRIN Inc., Placebo + Izokibep (NCT05905783)
- 2023-04-26Results posted on the registry: Novartis Pharmaceuticals, Secukinumab 300 mg, s.c. + Prednisolone (NCT03765788)
- 2023-03-31Also stopped (withdrawn): Novartis Pharmaceuticals, Secukinumab 300 mg (NCT04488185)
- 2023-03-21Results posted on the registry: AbbVie, Risankizumab (NCT04102007)
- 2023-03-21Results posted on the registry: Eli Lilly and Company, Mirikizumab (NCT03556202)
- 2023-03-21Also stopped (terminated): Eli Lilly and Company, Mirikizumab (NCT03556202)
- 2023-03-15Also stopped (withdrawn): Innovaderm Research Inc., Bimekizumab (NCT05499416)
- 2023-03-14Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab 300 mg + Secukinumab 150 mg (NCT05767034)
- 2023-03-09Results posted on the registry: Novartis Pharmaceuticals, Placebo + GP2017 (adalimumab biosimilar) (NCT03259074)
- 2023-03-07Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab + Placebo (NCT05758415)
- 2023-02-10Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab + Placebo (NCT05722522)
- 2022-11-30Also stopped (terminated): Eli Lilly and Company, Ixekizumab (NCT03848403)
- 2022-11-21Phase 3 first posted: ACELYRIN Inc., Izokibep + Placebo to izokibep (NCT05623345)
- 2022-10-10Results posted on the registry: UCB Biopharma SRL, Bimekizumab + Secukinumab (NCT03536884)
- 2022-10-06Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab (NCT05569174)
- 2022-08-15Results posted on the registry: Novartis Pharmaceuticals, secukinumab (NCT03031782)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision